2015
DOI: 10.5891/jafps.41.71
|View full text |Cite
|
Sign up to set email alerts
|

Rhodomyrtone, an Antimicrobial Acylphloroglucinol, in the Peel of<i> Myrciaria dubia</i> (Camu-camu)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 12 publications
0
1
0
Order By: Relevance
“…In the search for a novel antibiotic with a new mode of action, the very distinct antibacterial potency of rhodomyrtone attracted our research group to work on this target molecule. The compound presented extremely strong and broad-spectrum activity against Staphylococcus aureus [3][4][5][6], Enterococcus faecalis [7], Streptococcus pyogenes [8], Strptococcus mutans [9], Cutibacterium acnes [9,10], capsule-forming Streptococcus pneumoniae [11], Bacillus cereus [12] and endosporeproducing Clostridium difficile [13]. Of interest, this compound was found to be highly potent against problematic multidrug-resistant isolates, including methicillin-resistant S. aureus (MRSA) [14,15], vancomycin-intermediate S. aureus (VISA) and vancomycin-resistant enterococci (VRE) [16], with the MIC values at concentrations comparable with or superior to last-resort antibiotics in the glycopeptide group.…”
Section: Introductionmentioning
confidence: 99%
“…In the search for a novel antibiotic with a new mode of action, the very distinct antibacterial potency of rhodomyrtone attracted our research group to work on this target molecule. The compound presented extremely strong and broad-spectrum activity against Staphylococcus aureus [3][4][5][6], Enterococcus faecalis [7], Streptococcus pyogenes [8], Strptococcus mutans [9], Cutibacterium acnes [9,10], capsule-forming Streptococcus pneumoniae [11], Bacillus cereus [12] and endosporeproducing Clostridium difficile [13]. Of interest, this compound was found to be highly potent against problematic multidrug-resistant isolates, including methicillin-resistant S. aureus (MRSA) [14,15], vancomycin-intermediate S. aureus (VISA) and vancomycin-resistant enterococci (VRE) [16], with the MIC values at concentrations comparable with or superior to last-resort antibiotics in the glycopeptide group.…”
Section: Introductionmentioning
confidence: 99%